Paul Weiss Adds Robert Masella as M&A Partner
The New York firm has hired a former Bank of America Merrill Lynch managing director to its Corporate Department's M&A Group.
Updated on Nov. 17, 2026 in Corporate Finance

Paul, Weiss, Rifkind, Wharton & Garrison LLP has added Robert F. Masella as a partner in its M&A Group within the Corporate Department in New York. Masella is a former Bank of America Merrill Lynch managing director with decades of experience advising public and private companies on M&A transactions.
Why it matters
The hire adds transaction capacity in New York at a firm with more than 1,500 lawyers, with a particular emphasis on life sciences deals. Masella's experience advising on pharmaceutical and medical-device acquisitions bears directly on the firm's corporate practice.
Paul, Weiss employs more than 1,500 lawyers, and the announcement does not quantify Masella's transaction volume or the value of deals he has advised. The announcement also does not specify his start date or the terms of his partnership.
The players
Paul, Weiss, Rifkind, Wharton & Garrison LLP
A large New York-based international law firm with a major corporate and M&A practice that represents public companies, private equity funds, and financial institutions.
Robert F. Masella
A former Bank of America Merrill Lynch managing director who has advised on life sciences and other M&A transactions for decades.
The details
Masella joins the firm's M&A Group in New York and brings a practice covering public and private M&A, dual-track M&A/IPO processes, joint ventures, licensing and collaboration agreements, and spin-offs. He previously advised SpringWorks Therapeutics on its acquisition by Merck KGaA, Versanis Bio on its acquisition by Eli Lilly, and Teleflex on its acquisition of Biotronik's Vascular Intervention business.
Timeline
November 17, 2026: Paul, Weiss announces Masella's hire as M&A partner in New York.
Market Dynamics
Masella's record of advising on pharmaceutical acquisitions, including Merck KGaA's purchase of SpringWorks Therapeutics and Eli Lilly's purchase of Versanis Bio, places him within a continuing wave of large-pharma acquisitions of biotech companies. His experience at a major investment bank gives the firm a partner who has worked on the sell-side and buy-side of such deals.
For clients weighing a sale, merger, or spin-off, the hire gives the firm an additional New York partner with M&A and life sciences deal experience. The announcement does not indicate any change in fees or services for existing clients.
The takeaway
Lateral partner hires in M&A often signal where a firm expects deal demand to grow, and this hire points to continued emphasis on life sciences transactions. Readers tracking law firm competition can watch whether similar lateral moves follow in the sector.
Further reading
Explore more in Corporate Finance coverage for context on deal-making and law firm hiring.
Source note: This article includes information reported by Globallegalchronicle.






